Pfizer-Arvinas' breast cancer treatment cuts progression for some patients in study
An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.
First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.
Study Reveals Genetic Differences, Disparities in Treatment for Metastatic Breast Cancer
Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.
HER2DX Test Transforms Treatment Decisions in HER2+ Breast Cancer
A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's shares down 36% before the bell.
Arvinas Shares Dive on Trial Results for Metastatic Breast Cancer Treatment
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer. Shares were trading around $10.35. The stock is down 61% over the last year.
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy (update)
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Triple-Negative Breast Cancer (TNBC): Understanding Diagnosis and Treatment
TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.
In China, a designer rethinks lingerie for women who have had breast cancer surgery
The founder of Ginger Ah, China's first lingerie brand to develop both bras and the artificial breasts, says they struggle to ...
Medscape1d
Chemotherapy Linked to Long-Lasting Health Decline in Breast Cancer Survivors
Women with breast cancer who receive chemotherapy experienced a lasting decline in physical health, a new study found.
Inflammatory Breast Cancer (IBC): A Comprehensive Guide to Symptoms, Treatment, and Prevention
IBC is a rare, aggressive breast cancer with higher rates in younger women and those of African descent, requiring a ...
Breast cancer deaths rates for older women have been declining for years. Not anymore
Breast cancer is the second leading cause of cancer deaths in women in the U.S., killing more than 42,000 last year ...
On Her Mind: State representative working to close gaps in women's healthcare while battling breast cancer
Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...
CURE7h
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.
Bra fitting event at Dillard's supports breast cancer education
A special event at Dillard's in the Crestview Hills Town Center is offering a unique opportunity to support breast cancer education.
ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...